UCB (OTCMKTS:UCBJF) Shares Gap Down – Should You Sell?

Shares of UCB SA (OTCMKTS:UCBJF) gapped down prior to trading on Tuesday. The stock had previously closed at $305.59, but opened at $292.20. UCB shares last traded at $292.20, with a volume of 51 shares changing hands.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Jefferies Financial Group raised UCB to a “hold” rating in a report on Monday, August 3rd. Stephens reaffirmed an “overweight” rating on shares of UCB in a report on Wednesday, October 21st. Finally, Piper Sandler restated a “neutral” rating on shares of UCB in a research report on Wednesday, July 22nd. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, UCB presently has a consensus rating of “Moderate Buy”.

UCB Trading Down 4.4%

The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The business’s fifty day moving average price is $249.94 and its 200-day moving average price is $285.63.

About UCB

UCB is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for people living with severe diseases. Its primary therapeutic areas are neurology and immunology, with research activities spanning conditions such as epilepsy, myasthenia gravis, Parkinson’s disease, psoriasis, psoriatic arthritis, axial spondyloarthritis and other immune-mediated disorders.

The company’s medicines include Bimzelx (bimekizumab), an immunology treatment; Cimzia (certolizumab pegol), used for several inflammatory conditions; and a portfolio of neurological therapies that includes Briviact (brivaracetam), Keppra (levetiracetam), Fintepla (fenfluramine) and Nayzilam (midazolam).